Vimentin Regulates Alternative Polyadenylation and mTOR Signaling via ARVCF to Promote B Cell Lymphoma Progression
Human Mutation · 2025-01 · 2025 (1)
DOI: 10.1155/humu/1463685 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Mutation, online erschienen am 28.09.2025. Verfasst von Lujing Shao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, East Hospital Affiliated to Tongji University, Tongji University School of Medicine, Tongji University, Shanghai, China. Hauptthemen laut MEDLINE: TOR Serine-Threonine Kinases, Polyadenylation, Vimentin, Lymphoma, B-Cell. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Vimentin (VIM), a cytoskeletal protein implicated in tumor progression, has been associated with poor prognosis in B cell lymphomas. Alternative polyadenylation (APA), a posttranscriptional mechanism that modulates mRNA isoforms via 3 ′ UTR length changes, is frequently dysregulated in cancer. The interaction between VIM and APA in B cell lymphoma remains poorly understood.
Methods
We performed RNA‐seq, APA analysis (DaPars), and proteomic profiling in wild‐type and VIM‐knockout (VIM‐KO) B cell lymphoma cells (A20 and M12). Functional assays including CCK‐8, EdU, Western blot, and ARVCF overexpression were used to explore the regulatory axis involving APA and mTOR signaling.
Results
VIM deletion in B cell lymphoma cells triggered widespread transcriptome remodeling, inducing 4089 APA shortening events that preferentially targeted prosurvival pathways, for example, mTORC1, G2‐M checkpoint. Strikingly, RRAGA—a critical mTOR activator—underwent 3 ′ UTR shortening, concomitant with ARVCF downregulation in proteomic profiles. Functional rescue experiments demonstrated ARVCF’s dual role in maintaining RRAGA 3 ′ UTR length and suppressing mTOR‐EIF4G1 signaling, ultimately inhibiting lymphoma proliferation.
Conclusion
This study reveals a novel VIM–ARVCF–RRAGA–mTOR axis in B cell lymphoma, linking cytoskeletal disruption to APA‐mediated oncogenic signaling. VIM loss drives APA shortening and mTOR activation via ARVCF downregulation, promoting lymphoma progression. These findings offer mechanistic insight and potential targets for therapeutic intervention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, East Hospital Affiliated to Tongji University, Tongji University School of Medicine, Tongji University, Shanghai, China.
- Tongji Hospital Affiliated to Tongji University, Tongji University School of Medicine, Tongji University, Shanghai, China.
- Department of Forensic Medicine, School of Basic Medical Sciences, Fudan University, Shanghai, China.
ORCID-Profile: Chunyan Dong, Qianling Ye
Zitieren
APA
Shao, L., Xing, Q., Xiong, Y., Jin, K., Li, Q., Dong, C., & Ye, Q. (2025). Vimentin Regulates Alternative Polyadenylation and mTOR Signaling via ARVCF to Promote B Cell Lymphoma Progression. Human Mutation, 2025(1). https://doi.org/10.1155/humu/1463685
Vancouver
Shao L, Xing Q, Xiong Y, Jin K, Li Q, Dong C, et al. Vimentin Regulates Alternative Polyadenylation and mTOR Signaling via ARVCF to Promote B Cell Lymphoma Progression. Human Mutation. 2025;2025(1). doi:10.1155/humu/1463685
BibTeX
@article{Shao2025,
author = {Shao, Lujing and Xing, Qianke and Xiong, Yao and Jin, Kaidi and Li, Qi and Dong, Chunyan and Ye, Qianling},
title = {Vimentin Regulates Alternative Polyadenylation and mTOR Signaling via ARVCF to Promote B Cell Lymphoma Progression},
journal = {Human Mutation},
year = {2025},
volume = {2025},
number = {1},
doi = {10.1155/humu/1463685}
}
EUVIMED